Solid Biosciences to Participate at the Truist Securities BioPharma Symposium
Solid Biosciences (Nasdaq: SLDB), a company focused on developing precision genetic medicines for neuromuscular and cardiac diseases, has announced its participation in an upcoming industry event. Chief Medical Officer Gabriel Brooks, M.D. will be part of a Genetic Medicine Panel at the Truist Securities BioPharma Symposium on November 7, 2024, at 1:45 p.m. ET in New York. Institutional investors can arrange meetings with management through their Truist representatives.
Solid Biosciences (Nasdaq: SLDB), un'azienda focalizzata nello sviluppo di medicine genetiche di precisione per malattie neuromuscolari e cardiache, ha annunciato la sua partecipazione a un prossimo evento del settore. Il Direttore Medico Gabriel Brooks, M.D. sarà parte di un panel sulla Medicina Genetica al Truist Securities BioPharma Symposium il 7 novembre 2024, alle 13:45 ET a New York. Gli investitori istituzionali possono organizzare incontri con la direzione attraverso i loro rappresentanti Truist.
Solid Biosciences (Nasdaq: SLDB), una empresa enfocada en el desarrollo de medicamentos genéticos de precisión para enfermedades neuromusculares y cardíacas, ha anunciado su participación en un próximo evento de la industria. El Director Médico Gabriel Brooks, M.D. formará parte de un panel sobre Medicina Genética en el Truist Securities BioPharma Symposium el 7 de noviembre de 2024, a la 1:45 p.m. ET en Nueva York. Los inversores institucionales pueden organizar reuniones con la gerencia a través de sus representantes de Truist.
솔리드 바이오사이언스 (Nasdaq: SLDB)는 신경근육 및 심장 질환을 위한 정밀 유전자 의약품 개발에 주력하는 회사로, 다가오는 산업 이벤트에 참여한다고 발표했습니다. 의학 책임자 가브리엘 브룩스 박사가 2024년 11월 7일 오후 1시 45분 ET에 뉴욕에서 열리는 트루이스트 증권 바이오파마 심포지엄의 유전자 의약품 패널에 합류할 예정입니다. 기관 투자자는 트루이스트 대표를 통해 경영진과의 회의를 조정할 수 있습니다.
Solid Biosciences (Nasdaq: SLDB), une entreprise axée sur le développement de médicaments génétiques de précision pour les maladies neuromusculaires et cardiaques, a annoncé sa participation à un prochain événement de l'industrie. Le médecin chef Gabriel Brooks, M.D. fera partie d'un panel sur la médecine génétique lors du Truist Securities BioPharma Symposium le 7 novembre 2024 à 13h45 ET à New York. Les investisseurs institutionnels peuvent organiser des réunions avec la direction par l'intermédiaire de leurs représentants Truist.
Solid Biosciences (Nasdaq: SLDB), ein Unternehmen, das sich auf die Entwicklung präziser genetischer Medikamente für neuromuskuläre und kardiale Erkrankungen konzentriert, hat seine Teilnahme an einer bevorstehenden Branchenveranstaltung bekannt gegeben. Der medizinische Leiter Gabriel Brooks, M.D. wird Teil eines Panels zur genetischen Medizin beim Truist Securities BioPharma Symposium am 7. November 2024 um 13:45 Uhr ET in New York sein. Institutionelle Investoren können über ihre Truist-Vertreter Meetings mit dem Management arrangieren.
- None.
- None.
CHARLESTOWN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Gabriel Brooks, M.D., Chief Medical Officer, will participate in a Genetic Medicine Panel at the Truist Securities BioPharma Symposium on Thursday, November 7, 2024, at 1:45 p.m. ET in New York.
Institutional investors interested in meeting with management during the conference may reach out to their Truist representatives.
About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid’s mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit www.solidbio.com.
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com
Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
FAQ
When is Solid Biosciences (SLDB) participating in the Truist Securities BioPharma Symposium?
Who will represent Solid Biosciences (SLDB) at the Truist Securities BioPharma Symposium?
What type of medicines does Solid Biosciences (SLDB) develop?
How can investors meet with Solid Biosciences (SLDB) management at the Truist Symposium?
